All Outputs (4)

Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid prescribing: a descriptive analysis. (2024)
Journal Article
STOIBER, A., GRAY, G., SAILER, G., HUF, W. and TONNA, A. [2024]. Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid prescribing: a descriptive analysis. International journal of clinical pharmacy [online], Latest Articles. Available from: https://doi.org/10.1007/s11096-024-01852-5

Paxlovid® (nirmatrelvir and ritonavir) is the only licensed oral antiviral for COVID-19. Ritonavir is a potent inhibitor of cytochrome P450 enzymes causing numerous drug-drug interactions (DDIs). The aim of this study was to describe the frequency, t... Read More about Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid prescribing: a descriptive analysis..

Anwendungsbeobachtungs-Studie zur praktischen Anwendung von Klinischer Pharmazie bei COVID-19 Therapie. (2024)
Presentation / Conference Contribution
STOIBER, A., GRAY, G., SAILER, G., HUF, W. and TONNA, A. 2024. Anwendungsbeobachtungs-Studie zur praktischen Anwendung von Klinischer Pharmazie bei COVID-19 Therapie = Observational study on the practical application of clinical pharmacy in COVID-19 treatment. Presented at the 2024 Austrian Society for Hospital Pharmacy spring meeting, 24-25 May 2024, Vienna, Austria.

This presentation covers an observational study looking at Paxlovid as a treatment for COVID-19, undertaken at the Klinik Hietzing in Austria.

A description of pharmacists' interventions to optimise the treatment of adults with orally available Covid-drug, Paxlovid. (2024)
Presentation / Conference Contribution
STOIBER, A., GRAY, G., SAILER, G., HUF, W. and TONNA, A. 2024. A description of pharmacists' interventions to optimise the treatment of adults with orally available Covid-drug, Paxlovid. Poster presented at the 28th European Association of Hospital Pharmacists (EAHP) annual congress 2024 (EAHP 2024): sustainable healthcare; opportunities and strategies, 20-22 March 2024, Bordeaux, France.

Paxlovid ®, the only orally available COVID drug, consists of two main components: Nirmatrelvir and Ritonavir. Ritonavir is known for the potent inhibition of CYP (cytochrome P450) enzymes in the liver mainly of CYP3A4, resulting in a large number of... Read More about A description of pharmacists' interventions to optimise the treatment of adults with orally available Covid-drug, Paxlovid..

Bridging the theory-practice gap in pharmacy education using an authentic learning approach: a cross-sectional study. (2024)
Journal Article
DEPASQUALE, C. and GRAY, G. 2024. Bridging the theory-practice gap in pharmacy education using an authentic learning approach: a cross-sectional study. Pharmacy education [online], 24(1), pages 262-269. Available from: https://doi.org/10.46542/pe.2024.241.262269

Authentic learning environments highlight real-world relevance to students, contributing to readiness for practice. This study evaluated the impact of an educational activity on student pharmacist learning and personal/professional development. An ac... Read More about Bridging the theory-practice gap in pharmacy education using an authentic learning approach: a cross-sectional study..